1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ASCO-GI 2024 – Novartis Tightens Its Grip On The Radiopharmaceutical Space

 
• By Elizabeth Cairns

Lutathera yields a 72% reduction in the risk of progression or death in first-line GEP-NETs trial.  

Novartis logo building
• Source: Shutterstock

Last September, Jeff Legos, head of oncology at Novartis AG, described the results of the Phase III trial of the group’s radiopharmaceutical Lutathera as “quite remarkable”. Judging by the figures released today at the ASCO-GI meeting, he wasn’t kidding.

Key Takeaways
  • The NETTER-2 trial in first-line GEP-NETs shows that Lutathera improves PFS markedly over control
  • Novartis is one of the leaders in radiopharmaceuticals, and these new findings will help it retain that position
  • Overall survival

The data show a cut in the risk of disease progression or death by 72% when Lutathera is used as the first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from R&D

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.